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Abstract 
We discuss the concerns that the patenting activity in the new nanotechnologies could blur the line 
between what is considered a discovery and what can be considered as an invention.  We find that 
the nature of nanotechnology products, research, and the development agendas in science and 
engineering fields that include biomimetics pose a challenge to the present practice of including 
chemicals as eligible patent subject matter. After revisiting the historical development of patent 
law and noting its divergence from the developments in science and technology, we introduce the 
distinction between simple and complex machines as these relate to chemistry and 
nanotechnology. This distinction poses the question of what is the logical category of inventions 
that fall within patentable subject matter given that patent law was conceived to cover simple 
machines, not complex ones. 
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I. Symptoms 
The business excitement about nanotechnology1 is reflected by aggressive and 
intensive patenting strategies pursued by private and public entities attempting to 
stake a claim. Concurrent with this excitement are the many concerns about 
nanotechnology patents aired across a variety of publications ranging from law 
reviews to reports by non-governmental organizations (NGOs).2 At the European 
Union (EU) level, the question was asked “when is a nano-object a natural object (and 
thus not patentable) and when is it a constructed object?”3 This report also cites the 
work of the Action Group on Erosion, Technology and Concentration (ETC) and its 
claim that “the general doctrine in patent law, that products of nature cannot be 
patented, can be sidestepped because of the atomically engineered building 
techniques.” In addition, it reports on a seminar organized in 2003 at the European 
Parliament by a coalition including the ETC and the Green party where the concern is 
voiced that “one fundamental nano-patent might dominate developments in many 
industrial sectors, and enable the ownership of nature.”4 Another concern was 
formulated pertaining to the products of nanotechnology as “the progressive blurring 
of the invention/discovery interface under Article 27 TRIPS that may produce 
uncertainty over the types of nanoproducts that can be patented.” 5 The same 
commentator further contends that a “wide interpretation of that Article 27(1) may 
result in the monopolisation of fundamental molecules and compounds.”6 
However the concerns about the erosion of the invention–discovery distinction as a 
foundational principle in patent law are older than the buzz about nanotechnologies 
and nanomaterials. At the turn of the millennium, the general concern was voiced that 
“the old distinction between discovery and invention, the foundation of the patent 
system, has been obliterated.”7 In particular, “[n]ot merely are life-forms being 
                                                
1 We prefer the term ‘nanotechnologies’ over ‘nanotechnology’ to address the issues raised in 
the literature. In this paper we will however use the most appropriate of the two within the scope 
of the discourse or argument. Other terms used are nano-object, nano-patent, and nano-specific, 
all of which refer to physical, immaterial or tacit objects. 
2 ETC, Nanotech “Second Nature” Patents: Implications for the Global South, 2005, retrieved 5. 
5. 2011, <http://www.etcgroup.org/en/node/54>; ETC, The Big Downturn? Nanogeopolitics, 
2010, retrieved 5. 5. 2011, <http://www.etcgroup.org/en/node/5245>; I Barpujari, ‘The Patent 
Regime and Nanotechnology: Issues and Challenges’, Journal of Intellectual Property Rights 
vol. 15, 2010, pp. 206-213.  
3 4th Nanoforum Report: Benefits, Risks, Ethical, Legal and Social Aspects of Nanotechnology. 
Part 7: the need for and rise of new legislation and regulation caused by the emergency of 
Nanotechnology, 2nd Edition, October 2005: 244; all Nanoforum reports are available from the 
website http://www.nanoforum.org/. 
4TA Phelps, ‘The European Approach to Nanoregulation’, Nanoscale: Issues and Perspectives 
for the Nano Century 2007, pp. 189-210. 
5 DM Bowman, ‘Patently obvious: Intellectual property rights and nanotechnology’, Technology 
in Society vol. 29, 2007, pp. 307-315. 
6 Ibid. 
7 GC Gallopín, S Funtowicz, M O’ Connor, & J Ravetz, ‘Science for the twenty-first century: 
from social contract to the scientific core’, International Social Science Journal vol. 53, no. 168, 
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patented wholesale, but the identification of a possible function for a DNA sequence 
is sufficient for it to count as an 'invention', the property of he/she who stakes claim to 
it.”8 Speculation is running high on the problems that will arise from the patenting of 
nanotechnologies, and the proposed solutions take many forms.9 In addition, one early 
commentator listed potential utility problems that would arise from interdisciplinarity, 
inoperability, practical-utility, and upstream research.10 Another commentator, 
motivated by the investigation of the broad patenting of nanomaterials, also proposes 
the adoption of a strict utility requirement as the solution to the alleged tragedy of the 
anticommons in US nanotechnology.11 Yet another concern arises in light of the [US] 
Federal circuit’s decision in Madey v. Duke University,12 which narrows the scope of 
the experimental use defence to patent infringement, and thus is perceived to further 
stifle nanotechnology innovation.13 
In view of the potential seriousness and dire consequences for the public good 
expressed by these broad concerns over the ownership of nature and in terms of the 
invention–discovery dichotomy recapitulated above, we revisit patentable subject 
matter evolution from the perspective afforded by nanotechnology in general, and 
patent law in particular. We also keep in mind the ubiquitous convergence across all 
fields of science and technology14 – physical science, chemistry, biotechnology, 
systems biology, information and cognitive sciences – all contributing to the 
emerging nanotechnologies, which also blurs the line between science and 
technology.15 
In this paper we address these broad concerns about nanotechnology’s atomically 
engineered prowess and elaborate the question of the presumed blurring of the 
invention–discovery interface under Article 27 of the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS). For this purpose we first take a 
                                                                                                                                      
2001, pp. 219-229. The concern is voiced in the context of addressing the need posed by the 
challenges of sustainable development and the changing contexts at the beginning of the twenty-
first century that bring with them changes in the method and practice of science, which in turn 
require changes in scientific methods, criteria of truth and quality, and conceptual frameworks. 
8 Ibid. 7. 
9 McLennan and Rimmer recently surveyed the many challenges posed by nanotechnology to 
patent law, policy and practice : A McLennan, & M Rimmer, ‘Cosmo, Cosmolino: patent law 
and nanotechnology’ in M Rimmer, & A McLennan (eds.), Intellectual Property and Emerging 
Technologies: The New Biology, Edward Elgar Pub, 2012, pp. 255-290. 
10 DS Almeling, ‘Patenting Nanotechnology: Problems with the Utility Requirement’, Stanford 
Technology Law Review vol. N1, 2004, pp. 1-22. 
11 Reynolds, G, Nanotechnology and the Tragedy of the Anticommons: Towards a Strict Utility 
Requirement, 2009, retrieved 16. 02 2012, <http://www.uoltj.ca/articles/vol6.1-2/2009.6.1-
2.uoltj.Reynolds.79-114.pdf>. 
12 Madey v. Duke University, 307 F.3d 1351 (Fed. Cir. 2002). 
13 NM Zovko, ‘Nanotechnology and the Experimental Use Defense to Patent Infringement’, 
McGeorge Law Review vol. 37, 2006, pp. 129-156; W Helwegen, ‘The research exemption from 
a nanotechnology perspective’, European Intellectual Property Review vol. 327, 2010, pp. 341-
351. 
14 WS Bainbridge, & MC Roco, ‘Reality of Rapid Convergence’, Annals of the New York 
Academy of Sciences vol. 1093, no. 1, 2006, pp. ix-xiv. 
15 We note that the requirements for an invention in patent law from a UK and EPC perspective 
have been dealt with in great detail recently in: Pila, J, The Requirement for an Invention in 
Patent Law, Oxford University Press, USA, 2010. 
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different tack towards clarifying what nanotechnology is: nothing new. We argue that 
the so-called nanotechnologies are governed by the non-intuitive quantum mechanics 
that also governs chemical bonding, the convergence process in the sciences and 
technology, and introduce the distinction between simple and complex machines to 
guide the transition from classical to quantum mechanics within the context of 
technology patents in section II. In section III we survey the overall patenting activity 
in nanotechnology and discuss specific examples of patents involving carbon 
allotropes, self-assembling peptides, and mechanosynthesis of carbon. In the same 
section we also address the issue of size as it pertains to nanotechnology patents and 
patent disputes involving nanotechnology. In section IV we turn to the area of 
technology that is most intimately related to nanotechnology, that is, chemistry, its 
ontology and meandering history through the patent system. Finally, in section V, we 
establish that behind these ill-justified concerns lies a bigger problem, that of what 
constitutes chemical invention.  
II. Nature of Nanotechnology 
Nanotechnologies are both emerging and enabling.16 Nanotechnologies have elements 
of chemistry, physics, engineering, and smoothly cross over to biology and 
biotechnology, thus blurring classical twentieth century disciplinary boundaries. The 
disciplinary location of nanotechnology is complex and challenges the predominant 
reductionism that characterizes most classical disciplines.17 We note that 
nanotechnology as a discipline has been questioned, and what is observed is that 
“most scientists remain close to their original disciplines.”18 The issue of the often 
alluded convergence is not in the disciplines themselves, it is one of methods19 but 
also in the aggregation of disciplines in technology clusters.20 Above all, the 
nanotechnologies exploit effects that can be explained within the theory of quantum 
                                                
16 See for example: Baird, D, A Nordmann, & J Schummer, Discovering the nanoscale, IOS 
Press, 2004; D Baird, & T Vogt, ‘Societal and ethical interactions with nanotechnology “SEIN” 
- An Introduction’, Nanotechnology Law & Business vol. 1, no. 4, 2004, pp. 391-396; 
Schummer, J, & D Baird, Nanotechnology Challenges: Implications for Philosophy, Ethics and 
Society, World Scientific Publishing Company, 2006; Bainbridge, WS, Nanoconvergence: the 
unity of nanoscience, biotechnology, information technology, and cognitive science, Prentice-
Hall, 2007. 
17 Roco, MC, & WS Bainbridge, Societal implications of nanoscience and nanotechnology, 
Kluwer Academic Publishers, 2001; Roco, M, & W Bainbridge, Converging technologies for 
improving human performance: Nanotechnology, biotechnology, information science and 
cognitive science, 2003; S Loeve, ‘About a Definition of Nano: How to Articulate Nano and 
Technology?’, Hyle - Internantional Journal for Philosophy of Chemistry vol. 16, no. 1, 2010, 
pp. 3-18. 
18 V Mangematin, & S Walsh, ‘The future of nanotechnologies’, Technovation vol. 32, no. 3-4, 
2012, pp. 157-160. 
19 Speaks of a nanotechnological approach (method) in pharmaceutical technology: N Daum, C 
Tscheka, A Neumeyer, & M Schneider, ‘Novel approaches for drug delivery systems in 
nanomedicine: effects of particle design and shape’, Wiley Interdisciplinary Reviews: 
Nanomedicine and Nanobiotechnology vol. 4, no. 1, 2012, pp. 52-65. Biology inspired 
engineering: T Jovanovic-Talisman, & A Zilman, ‘Nanobiotechnology: building a basic 
nanomachine.’, Nature Nanotechnology vol. 6, no. 7, 2011, pp. 397-398. 
20 N Battard, ‘Convergence and multidisciplinarity in nanotechnology: Laboratories as 
technological hubs’, Technovation vol. 32, no. 3-4, 2012, pp. 234-244. 
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mechanics and that are often attributed to particle size.21 Nanotechnology, the 
umbrella term for all nanotechnologies, has elements of both science and technology. 
As such it is both an area of rapid scientific discovery, and one of accelerated 
technological development. Nanotechnology involves engineering at the quantum 
level, and immersion into scientific fields that defy common intuition. Much has been 
written on its nature; however, when one gets down to the bare bones of the issues 
that deal with nanomaterials, it is fundamentally chemistry. Chemistry is also a 
service science that can be applied in many technological fields. Another view is that 
“nanotechnology is only one potential future for chemistry.” 22 And, taking a more 
informed view “a number of research pathways developed over the last decades of the 
twentieth century – catalysis, supramolecular chemistry, biomimetic chemistry, soft 
chemistry, etc. – paved the way for nanotechnology and are sometimes relabeled 
nanochemistry.”23  
A. Engineering	  at	  the	  Quantum	  Level	  
Nanotechnology could be described as engineering at the quantum regime, but then, 
engineering at the quantum regime is exactly what chemistry has been all along. This 
regime, also known as quantum physics24 is the realm of the Planck scale (time, 
length, mass, energy, etc.), that is, the regime of the very small in all physical 
dimensions. At the Planck scale25 the common-sense intuitive concepts of size and 
distance break down. It is also not that the quantum scale gets turned off in 
macroscopic objects; it is just that the quantum scale effects dominate at the 
microscopic level.26 It can be said that the quantum physical regime is described by 
probability distributions of the set of outcomes of measurements of an observable. 
This apparent indeterminacy in quantum systems has nothing to do with errors of 
measurement, it is of a much more fundamental nature. However, this is also an area 
of physical theory that challenges human concepts of logic and intuition which make 
up a considerable part of reasoning used for establishing the degree of obviousness.27 
At the risk of labouring the point, the non-obviousness nature of quantum phenomena 
                                                
21 Nanoparticle definition 10–200 nm or whatever is most often cited. However there is no 
generally agreed definition of nanotechnology based on size. For a recent discussion on the 
definition see: G Liden, ‘The European commission tries to define nanomaterials.’, Ann Occup 
Hyg vol. 55, no. 1, 2011, pp. 1-5. In addition, the European Commission has recently issued 
recommendations on the definition of nanomaterial that include size considerations: [2011] OJ 
275/38. 
22 Bensaude-Vincent, B, Boundary Issues in Bionanotechnology: Editorial Introduction, 
retrieved 12. 3. 2012, <http://www.hyle.org/journal/issues/15-1/editorial_bensaude.htm>. 
23 Ibid. 
24 Physics is inclusive of chemistry although traditionally chemistry is not considered a sub-
division or sub-discipline of physics. The fact is that to gain expert knowledge of chemistry, a 
student must become well versed in the prevalent theories of physics, in particular quantum 
mechanics. Thus the term “quantum physics” is broader and includes chemistry. 
25 The Planck scale can refer to either a length scale or a time scale, the two being related by the 
uncertainty principle formulated by Werner Heisenberg.  
26 V Verdal, ‘Living in a Quantum World’, Scientific American vol. 304, 2011, pp. 38-43. 
27 In the EPO Guidelines C-IV, 11.4 it is stated that “[t]he term ‘obvious’ means that which does 
not go beyond the normal progress of technology but merely follows plainly or logically from 
the prior art, i.e. something which does not involve the exercise of any skill or ability beyond 
that to be expected of the person skilled in the art.” 
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cannot be ignored in a discussion of what constitutes patentable subject matter in 
general, and invention in particular. This quirk of nature ought not to be an excuse to 
consider any scientific discovery in this field an invention because of its non-
obviousness. There is often much confusion in the literature between discovery and 
non-obviousness but they are two different concepts belonging to different aspects in 
patent law. Discovery pertains to patentable subject matter, and the question of 
obviousness pertains to the inventive step or inventiveness. Still, the take home lesson 
here is not about the relationship between discovery and obviousness. The take home 
lesson ought to be that Nature’s quantum manifestations are ludicrous,28 and thus not 
accessible to the so-called common sense, which social and legal scholars are fond of 
invoking. In other words “[i]t is perhaps not surprising that, at small scales, things 
behave in strange and counterintuitive ways; after all, our intuitions have developed 
for dealing with objects much larger than individual atoms.”29 That is, in order to 
clarify the legal and policy issues, one is well advised not to mix up what the 
fundamental nature of the technical substance is with what the theoretical, legal and 
philosophical issues relevant for policy are. 1. Convergence	  
Not only have nanotechnologies been made possible by the convergence of several 
disciplines through the use of related methodologies, nanotechnologies are also in 
their nature intimately related to chemistry. The nanoscale is the scale at which 
chemistry takes place. The discipline of chemistry was preceded by alchemy, the goal 
of which was the transformation of ordinary matter into gold. In a metaphoric sense, 
material technologists today have achieved this goal. Today materials science and 
technology allows for the engineered creation of smart materials that turn ordinary 
matter into highly prized materials;30 we call it nanotechnology. What medieval 
alchemists could not have known is that to get to this desired state of affairs – turning 
ordinary materials into highly prized ones – they needed the help of physicists, 
engineers, biologists and computer scientists. This is called the convergence that leads 
to the phenomenon called nanosciences and technologies.31 
Eric Drexler32 started the debate around nanotechnologies and futuristic visions using 
both engine and creation in the title of his now famed book. Inadvertently or not, it 
points to the essence of the subject at hand, it has both mechanical and biological 
figments. Chemistry is not an engine, but it is involved in emergence (creation) of 
biological systems as such. If we are to associate creation with the growth and 
                                                
28 Ludicrous is the word of choice to convey the fact that many quantum phenomena are beyond 
what the human min dis willing, capable or trained to believe. 
29 Vogel, R, Pharmaceutical Economics and Public Policy, Pharmaceutical Products Press, 2006. 
at 5. 
30 For instance, nanotechnology research results point to the possibility of replacing rare earth 
elements used in electronics fabrication with nanomaterials made from more globally equally 
distributed chemical elements. While rare earth elements are per se not rare, their mining can be 
rather intensive and they are not found in all geographical regions in the way silicon, carbon, 
nitrogen or hydrogen are. 
31 Refer to either Schummer or Bainbridge in 16. 
32 Drexler, KE, Engines of creation: The coming era of nanotechnology, Anchor Press New 
York, 1987. 
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reproduction of living organisms, the engines of life are chemical processes.33 
Ultimately, what allows the assembly of nanoparticles, be it in natural or engineered 
processes, are chemical processes (better known as chemical reactions or interactions). 
That some aspects of nanotechnology are essentially, but not only, a further 
development in chemical sciences, is perhaps too subtle an issue to merit much 
attention beyond that which historians and philosophers of science like to devote to it. 
It is exactly this subtle point of the nature of what the technology in nanotechnology 
is about, however, that is most relevant to the legal disciplines, in particular to patent 
law. That is, be it in biological processes or in nanotechnological processes, what we 
are dealing with are chemical processes. If Drexler used the term ‘self-assemblers’ 
this was because he lacked knowledge about the nature of chemical processes, which 
are always self-assembling. Thus using engineering metaphors and those of 
mechanics seems obvious, but at the same time, it is misleading and detracts from the 
fundamental nature of the science that is the basis of this technology. Moreover, 
biomimetics is emerging as a strong nanotechnology engineering discipline, and it has 
no other aim than to discover and invent processes that are developed along life’s yet 
unravelled principles and that are presumed likely to be sustainable.34 Biomimetics35 
in itself is not new; engineers have often borrowed nature’s technical solutions and 
applied them to new inventions such as the design of aeroplanes following Leonardo 
da Vinci’s example of bird’s flight studies to inspire his proposed flying machines.  
However this is not a debate about classification of nanotechnology – claimed as 
the newest field of human endeavour36 – into a new discipline, it is an attempt at 
elucidating the nature of the  subject matter, namely nanomaterials,37 that we are 
subjecting to a specific legal regime, that of patent law. Next, for the purposes of 
illustration, we consider spin as one of the quirky manifestations of nature at the 
quantum scale. 2. Intuition	  and	  Spin	  
The electron – the fundamental particle involved in chemical bonding, the same 
electron that is the working agent in electronic devices, and the product of electrical 
                                                
33 Life can be viewed as a shuffling of energy through chemical processes mediated by an array 
of molecular structures. 
34 IC Gebeshuber, P Gruber, & M Drack, ‘A gaze into the crystal ball: Biomimetics in the year 
2059’, Proceedings of the Institution of Mechanical Engineers, Part C: Journal of Mechanical 
Engineering Science vol. 223, no. 12, 2009, pp. 2899-2918; B Bhushan, ‘Biomimetics: lessons 
from nature - an overview.’, Philosophical Transactions of the Royal Society A Mathematical, 
Physical & Engineering Sciences vol. 367, no. 1893, 2009, pp. 1445-1486; C Tamerler, D 
Khatayevich, M Gungormus, T Kacar, EE Oren, M Hnilova, & M Sarikaya, ‘Molecular 
biomimetics: GEPI-based biological routes to technology.’, Biopolymers vol. 94, no. 1, 2010, pp. 
78-94. 
35 Biomimetics is an interdisciplinary engineering field focused on the imitation of nature, not 
just at the mechanical level, but also at the atomic and molecular scales. 
36 G Marchant, & D Sylvester, ‘What Does the History of Technology Regulation Teach Us 
about Nano Oversight?’, The Journal of Law, Medicine & Ethics vol. 37, no. 4, 2009, pp. 724-
731.The claim made in the first paragraph is that “nanotechnology is the latest in a growing list 
of emerging technologies that includes nuclear technologies, genetics, … .” 
37 We focus on nanomaterials, the products of the technologies grouped under nanotechnology. 
This focus is necessary as patent law deals with products, processes or methods invented in any 
technology. 
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generators –  has a physical dimension called spin that can have a value of either +½ 
or −½. A chemist may refer in the same breath to an electron spin being ‘up’ or 
‘down’ and ‘orbital momentum’ that are assigned various discrete values thus 
enabling logical (mathematical) manipulation and computation. In fact, chemical 
bonding is – loosely speaking – governed by spin. A chemical bond is formed when 
two electrons with different spins are at the same energy level shared by two atoms. If 
the two electrons, for whatever reason, find themselves at the same energy level and 
with the same spin, then they will not contribute to the formation of a chemical bond 
by not remaining at that energy level. Together, spin and orbital momentum give the 
electron its angular momentum. Orbital angular momentum is of great significance in 
the type of bonding that the atom or molecule forms. Electron spin resonance is a 
technique used to study molecular species that have one unpaired electron (radicals). 
In the presence of a magnetic field, the unpaired electron will give a signature signal 
that allows inference about the presence and nature of such a molecular species.38 
Aside from the esoteric language of quantum mechanics and the various labels that it 
uses to abstractly handle the observable phenomena, spin is just not the kind of 
physical property that can easily be understood through common sense intuition. In 
the theory of quantum mechanics it allows for the understanding through abstraction 
of many atomic, molecular and material properties.  
Electron spin is of special interest in areas of solid-state memory devices where 
current research and development efforts explore this property.39 Beyond the 
implication of physical properties that elude present intuition, of which spin is but one 
example, there are more fundamental novelties associated with nanotechnology which 
are still being discovered.  
The concept of spin may only make sense to physicists and chemists. It is, however, 
but one of the fundamental concepts that permit an understanding of nanotechnology. 
With the formulation of the theory of quantum mechanics, and the discovery and 
study of the physical effects explained by it, it became necessary to develop a 
language appropriate to what was observed. That this language does not make sense 
to legal scholars is understandable, however unfortunate. Thus the necessity to 
translate the abstractions of the quantum world of chemistry to distinctions that are 
useful in the legal regime, and in particular in patent law, becomes acute when the 
technologies – nanotechnologies – that dominate scientific research and technological 
development are governed by its laws. We offer the distinction between simple and 
complex machines as one that could be useful for the task of translating the 
abstractions of the quantum world to that of the legal regime. One fundamental aspect 
of the novelty in the nanotechnologies is its potential for the manufacture and creation 
of complex systems (engines and machines) and the extension of those techniques to 
biomimetics, and ultimately to synthetic biology.  
                                                
38 Better known than electron spin resonance, is nuclear magnetic resonance, which is a 
technique widely used in medical imaging, but that, instead of exploiting electron spin, exploits 
proton spin. 
39  See for example: L Bogani, & W Wernsdorfer, ‘Molecular spintronics using single-molecule 
magnets’, Nature Materials vol. 7, no. 3, 2008, pp. 179-186; S Sanvito, ‘Organic spintronics: 
Filtering spins with molecules’, Nature Materials vol. 10, no. 7, 2011, pp. 484-485. 
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3. Simple	  and	  Complex	  Machines	  
“Quantum mechanics is to atoms and molecules what classical mechanics is to 
engines.”40 While the science and technology that have served the industrial 
development of chemicals have been using quantum mechanics as a theoretical basis, 
the mechanical world of steam engines and electric machines is still using classical 
mechanics. These two very distinct science and technology areas have been served by 
the same patent system; however, not surprisingly, the practice in the two areas has 
diverged. The patent system has treated chemicals with the same reductionist 
approach that it uses for steam engines and can openers. We question the validity of 
this approach, and ask what consequences this may have in elucidating the 
patentability of nanotechnology inventions. 
Understanding the differences between classical and quantum mechanics can help one 
to understand better the divergence in patent law practice between classical machines 
and chemical-related inventions. The juxtaposition of the two different models of 
nature – classical mechanics and quantum mechanics – allows for the questioning of 
the rationale applied to justify the divergence in patent practice between (a) chemicals, 
biotechnology, and genes, and (b) classical electric, electronic, or mechanical 
machines. In nanotechnology, the world of mechanics (b) joins the chemical world (a), 
and one is left pondering where to classify it. However this is not a problem of patent 
classification, it is a problem with epistemic classification of a technology that 
challenges existing models (theories) and common sense. The preoccupation with the 
classification of the technology then leads to the question of what is truly created by 
humans, and what is created by nature itself.  
A steam engine from the heyday of the industrial revolution is an engine that 
transforms one form of energy into another and there is no doubt that human 
ingenuity and creativity produced that engine. In contrast molecular motors such as 
myosin41 or kinesin,42 which perform exactly the same function of converting one 
form of energy into another, have evolved through natural processes and without 
human intervention. These are two distinct categories of engine. The first kind is 
called a (Cartesian) simple engine, and the second kind is a (von Neumann) complex 
engine. 
Fuelling much of the hype on nanotechnology is Drexler’s famous book Engines of 
Creation. One can argue that these ‘engines of creation’ imagined by Drexler are 
neither standard mechanical machines or simple machines, nor are they complex 
systems within the von Neumann model of complex machines.43 Drexler’s assemblers 
                                                
40 See 29. Furthermore Lloyd offers the view that “all interactions between particles in the 
universe convey not only energy but also information.” That is, particles not only collide or 
interact, but they also exchange information, thus compute. In brief, as the universe unfolds it is 
actually computing itself in what is called a dynamical evolution. “The digital revolution today 
is merely the latest in a long line of information-processing revolutions stretching back through 
the development of language, the evolution of sex, and the creation of life, to the beginning of 
the universe itself.” 
41 Myosin comprises a family of adenosine tri-phosphate (ATP) dependent motor proteins that 
are responsible for muscular contraction. 
42 Kinesin proteins are also motor proteins and are powered by hydrolysis of ATP.  
43 X Guchet, & B Bensaude-Vincent, ‘Nanomachine: Technological Concept or Metaphor?’ in F 
Jotterand (ed.), Emerging Conceptual, Ethical and Policy Issues in Bionanotechnology, 
Springer, 2008, pp. 27-41. 
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and “Grey Goo” take a purely exploitative view of nature adopting a bottom-up 
approach to assembly in an indiscriminate atom-by-atom manner.44 In the Cartesian 
model of a machine each part has been individually designed to perform a specific 
task and when all parts are assembled according to the engineer’s design, it will 
perform in a perfectly predictable and understandable way. A classical steam engine 
or an egg-beater are good examples of Cartesian machines. Cartesian machines and 
simple engines exhibit behaviours that can be completely described. By contrast a von 
Neumann complex machine “cannot be deduced and does not pre-exist in the mind of 
its designer.”45 This complex machine, or automaton, is capable of such complicated 
behaviour “that it is impossible to describe it completely and unambiguously” as to its 
functions. 46 That is, as von Neumann posited, there is a threshold of complexity at 
which “the structure of an object becomes simpler than the description of its 
properties.”47 Thus, while one can document procedures for assembling both 
Cartesian and von Neumann machines, the latter’s behaviour is more complex than 
what our representational methods can describe. Good examples of complex machines 
are molecules such as myosin or kinesin. Molecular structure can be completely 
determined by the physical methods of natural science, however, the function of such 
a molecule or how it performs that function are often surprising and very much the 
subject and object of discovery. This is in fact what we observe with nanomaterials. 
III. Nanotechnology Patents 
Nanotechnology patents and nanotechnology are the topic of many dedicated journals 
such as Nature Nanotechnology or Recent Patents in Nanotechnology. The European 
Patent Office (EPO) has addressed the expectation and resulting numerous 
applications by creating an internal working group on nanotechnology.48 There is 
significant consensus that nanotechnology and other enabling technologies could help 
society deal with many of the challenges of this century, including those of climate 
change, energy, health, food and agriculture, communication, and security.49 In 
                                                
44 The Grey Goo model has been discredited by chemists, and abandoned by its author: for a 
deeper analysis of the controversy see O Bueno, ‘The Drexler-Smalley Debate on 
Nanotechnology: Incommensurability at Work?’ in J Schummer, & D Baird (eds.), 
Nanotechnology challenges: implications for philosophy, ethics and society, World Scientific 
Pub., 2006, pp. 29-48. 
45 See 43 at 31. 
46 Ibid. 
47 J-P Dupuy, & A Grinbaum, ‘Living with Uncertainty: towards the Ongoing Normative 
Assessment of Nanotechnology’ in J Schummer, & D Baird (eds.), World Scientific Pub., 2006, 
pp. 287-314.  
48 M Scheu, V Veefkind, Y Verbandt, & E Galan, ‘Mapping nanotechnology patents: The EPO 
approach’, World Patent Information vol. 28, 2006, pp. 204-211. 
49 The literature about nanotechnology applications is vast. Nanotechnology is a general purpose 
technology, thus its methods and application affect all areas of technology. See for example: TA 
Faunce, ‘Nanotherapeutics: new challenges for safety and cost-effectiveness regulation in 
Australia’, Medical Journal of Australia vol. 186, no. 4, 2007, pp. 189-191; TA Faunce, ‘Global 
Medicine and Human Biosecurity: Private Interests, Policy Dilemmas, and the Calibration of 
Public Health Law’, The Journal of Law, Medicine & Ethics vol. Winter, 2007, pp. 629-642; 
FAO/WHO, ‘FAO/WHO Expert Meeting on the Application of Nanotechnologies in the Food 
and Agriculture Sectors: Potential Food Safety Implications’, FAO/WHO Expert Meeting on the 
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addition, quantum dots are finding applications across a range of sectors that further 
demonstrate how diverse the various nanotechnologies are.50 Accordingly 
nanotechnology discoveries and inventions are being claimed in all areas of science 
and technology in a fashion reminiscent of the gold rush.51 Besides the actual study of 
concrete patent specifications or applications, it is useful to look at the level of 
activity reported in the various jurisdictions in both developed and transitional 
economies, or to study at length the data available.52 
A. Inventions	  and	  Technologies	  
Nanotechnology-related inventions are numerous. At the EPO these fall into two main 
categories: inventions with a controlled geometric size of at least one functional 
component, and inventions relating to equipment and methods for analysis, 
measurement, processing, manipulation and fabrication below 100 nm.53 Getting a 
firm grip of the number of patents in this category is difficult as it depends on the 
search strategies, databases, keywords, and patent classifications used, which make 
the numbers from different studies incomparable. In any case the various reports on 
the analysis of bibliographic data on nanotechnology-related patent applications and 
patents provide some guidance to the overall inventive activity in the area.  
In 2010, the number of US patents granted, which were officially classified in the 
nanotechnology class54 by the United States Patent and Trademark Office (USPTO) 
                                                                                                                                      
Application of Nanotechnologies in the Food and Agriculture Sectors: Potential Food Safety 
Implications 2009, pp. 1-104; R Kalpana Sastry, HB Rashmi, & NH Rao, ‘Nanotechnology for 
enhancing food security in India’, Food Policy vol. 36, no. 3, 2011, pp. 391-400; LJ Frewer, W 
Norde, & A Fischer, ‘Nanotechnology in the Agri-Food Sector: Implications for the Future’, 
Implications for the Future 2011, pp. 328. 
50 CA Charitidis, A Golnas, F Chouliaras, N Arpatzanis, CA Dimitriadis, JI Lee, & C Bakolias, 
‘QD technology and market prospects in the sectors of space exploration, biomedicine, defense, 
and security’, physica status solidi (c) vol. 5, no. 12, 2008, pp. 3872-3876; JE Riviere, 
‘Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum 
dots.’, Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology vol. 1, no. 1, 
2009, pp. 26-34; K Sanderson, ‘Quantum dots go large.’, Nature vol. 459, no. 7248, 2009, pp. 
760-761. 
51 Hebert, P, Nanotechnology gold rush yields crowded, entangled patents, 2005, retrieved 5. 08. 
2010, <http://www.luxresearchinc.com/press/RELEASE_IPreport.pdf>; M Lemley, ‘Patenting 
nanotechnology’, Stanford Law Review vol. 58, 2005, pp. 601-630; R Bawa, SR Bawa, & SB 
Maebius, ‘The Nanotechnology Patent ‘Gold Rush’’, Journal of Intellectual Property Rights vol. 
10, 2005, pp. 426-433; J Fromer, ‘A Psychology of Intellectual Property’, Northwestern 
University Law Review vol. 104, no. 4, 2010, pp. 1441-1510. 
52 X Li, Y Lin, H Chen, & M Roco, ‘Worldwide nanotechnology development: a comparative 
study of USPTO, EPO, and JPO patents (1976–2004)’, Journal of Nanoparticle Research vol. 9, 
2007, pp. 997-1002; X Li, H Chen, Y Dang, Y Lin, C Larson, & M Roco, ‘A longitudinal 
analysis of nanotechnology literature: 1976–2004’, Journal of Nanoparticle Research vol. 10, 
2008, pp. 3-22; X Li, D Hu, Y Dang, H Chen, M Roco, & C Larson, ‘Nano Mapper: an Internet 
knowledge mapping system for nanotechnology development’, Journal of Nanoparticle 
Research vol. 11, 2009, pp. 529-552. 
53 Verbandt, Y, C Kallinger, M Scheu, & W Förster, Nanophotonics technology watch at the 
European Patent Office, 2008, retrieved 13. 03 2012, 
<http://link.aip.org/link/PSISDG/v6988/i1/p69880W/s1&Agg=doi>. 
54 USPTO Class 977 and a cross reference art collection; retrieved 9.11.2011 
<http://www.uspto.gov/web/patents/classification/uspc977/sched977.htm>. Besides the US 
classification, the EPO, JPO and World Intellectual Property Organization (WIPO) 
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was 5,962.55 According to a patent publication analysis for USPTO, EPO, and Japan 
Patent Office (JPO) data from 2005–2007, Switzerland ranks 11th on a list headed by 
the US, Japan, Germany, and China.56 For example, more than 350 nanotechnology-
related inventions57 assigned to 140 Swiss entities were found up to 2010.58 Another 
study finds that China has an above-average growth rate in nanotechnology patents, 
and Germany a below-average rate.59 
A breakdown of the State Intellectual Property Office of the People's Republic of 
China (SIPO) patent applications by country or region from 1991 to 2006 puts China 
at the top of the list with 11,065, followed by the US with 1,072, Japan with 623, 
Republic of Korea with 409, Taiwan with 305, and by Germany, the Netherlands, and 
France, all with more than 100 applications pending.60 It is not surprising that China 
heads this list, accounting for approximately 77% of all nanotechnology patent 
applications in the SIPO database. In Taiwan, courts issued specific guidelines which 
call for the close scrutiny of invention step, utility and enablement to provide 
assistance with nano-based Chinese herbal medicine (CHM) patents.61 In China the 
particular case of nano-based CHM patents has generated the concern that there is an 
irrational exuberance in patenting these applications which “will surely act as a 
barrier to innovation and invention in the emerging biopharmaceutical industry and 
nano based CHM market.”62 
                                                                                                                                      
(International Patent Classification, IPC) have also established criteria on patent classification 
for nanotechnology-related inventions. The EPO’s nanotechnology European Classification 
System (ECLA) sub-class is B82Y and it comprises nine main groups; retrieved 9.11.2011 
<http://www.epo.org/news-issues/issues/classification/nanotechnology.html>. See also Watal, A, 
& TA Faunce, Patenting Nanotechnology: Exploring the Challenges, retrieved 28. 6. 2011, 
<http://www.wipo.int/wipo_magazine/en/2011/02/article_0009.html>. 
55 S Maebius, & D Jamison, ‘Nanotechnology Law & Business Turns Seven’, Nanotechnology 
Law & Business vol. 7, 2010, pp. 1.  
56 See Chen, H, & M Roco, Mapping Nanotechnology Innovations and Knowledge: Global and 
Longitudinal Patent and Literature Analysis, Springer, 2008; A McGibbon, C Soltmann, & R 
Boutellier, ‘Assessing the Swiss Nanotechnology Landscape’, Nanotechnology Law and 
Business no. 7, 2010, pp. 366-379. Appendix, Table A1 at 299 for the complete ranking. 
57 Inventions is used here instead of patents because in this study what was counted were the 
number of patent families, not the number of patents. Depending on how significant and what 
market it is destined for, an invention may have a large number of patents in its patent family. 
Each member of a patent family counts as a single patent, however the ensemble counts as just 
one invention. 
58 See McGibbon et. al. in 56. 
59 Preschitschek, N, & D Bresser, Nanotechnology patenting in China and Germany – a 
comparison of patent landscapes by bibliographic analyses, 2010, 
<http://www.businesschemistry.org/article/?article=109>. 
60 R Parker, C Ridge, C Cao, & R Appelbaum, ‘China’s Nanotechnology Patent Landscape: an 
Analysis of Invention Patents Filed with the State Intellectual Property Office’, Nanotechnology 
Law and Business vol. 6, 2009, pp. 524-539.; East Asian patent application filers (China, Japan, 
and the Republic of Korea) using the Patent Cooperation Treaty (PCT) system now outnumber 
those in North America and Western Europe as of 2010. Source: WIPO statistics, downloadable 
at www.wipo.int/ipstats/en/statistics/pct/ (26.5.2011). 
61 JI-H Hsiao, ‘Nanotechnology Meets Chinese Herbal Medicine: an Introduction to the 
Patenting of Nano-Based Chinese Herbal Medicine in Taiwan’, Nanotechnology Law Business 
vol. 7, 2011, pp. 80-96.  
62 T-P Dong, & C-H Sung, ‘Exuberance or Bubble? Study of Nano-Based Herbal Medicine 
Patents in the PR China’, Journal of Intellectual Property Rights vol. 16, 2011, pp. 225-234. 
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For Russia, patent analysis indicates that between 1997 and 2005 nanotechnology 
patent activity increased considerably, and that there is a specialization in nano-optics 
and nano-mechanics, whereas nano-biotechnology shows no such specialization.63 
This gives an indication of both the diversity of the technological fields and the fact 
that there are different regional specializations. A brief sampling of the 
nanotechnology-related patents on record follows, all of which involve some aspect of 
the chemistry of carbon. 1. Patents	  Involving	  Carbon	  Allotropes	  
Carbon allotropes64 are all the rage in nanomaterials, and have been the subject of 
much of the pioneering research that led to the development of the nanotechnology.65  a) Buckyballs	  
The case of buckyballs66 is illustrative of a nanomaterial that existed in nature but was 
only discovered in nature after its laboratory discovery.67 The patent applications for 
fullerenes – the broader class of carbon molecules to which buckyballs belong – have 
often been interpreted to mean ownership of the molecule, and that by interpolation, 
techniques for the precise manipulation of atoms open up a whole new terrain for 
private ownership, such as is the case of genes which are claimed to be “controlled by 
patents.”68  As it was for buckyballs, so it has been for many other developments in 
science in technology where the discovery of a new aspect of nature, or a new law of 
nature, leads to considerable research activity in the pursuit of what are thought to be 
potential beneficial applications that can be successfully commercialized. Patents 
applications involving fullerenes have been filed and granted; however, after a great 
deal of initial excitement about their potential for revolutionary applications from 
rocket fuels to drug carriers, the attention and patent filing activity have turned to 
other nanomaterials.69 In Europe between 300 and 400 businesses, research 
institutions, universities and independent inventors hold patents or applications 
                                                
63 T Reiss, & A Thielmann, ‘Nanotechnology Research in Russia - an Analysis of Scientific 
Publications and Patent Applications’, Nanotechnology Law & Business vol. 7, 2011, pp. 387-
404. 
64 Allotropy is the variation of physical properties without change of substance to which certain 
elementary bodies are liable. First noticed by Berzelius in the case of charcoal and diamond.  
(allotropy, n. Second edition, 1989; online version March 2011. 
<http://www.oed.com:80/Entry/5444>; accessed 31 May 2011. Earlier version first published in 
New English Dictionary, 1884.) 
65 J Luis Delgado, M Angeles Herranz, & N Martin, ‘The nano-forms of carbon’, Journal of 
Materials Chemistry vol. 18, no. 13, 2008, pp. 1417-1426. 
66 A buckyball is a carbon cage where the vertices are occupied by a carbon atom such that in its 
geometry it resembles a geodesic dome as invented by Buckminster Fuller. 
Buckminsterfullerene is a 60 carbon molecule having a van der Waals radius of about 1 
nanometre (nm). 
67 H Kroto, ‘New insights in to the mechanisms of fullerene and nanotube formation’, IEEE 
18th International Vacuum Nanoelectronics Conference 2005, pp. 1-37. 
68 Arnall, AH, Future technologies, today’s choices: nanotechnology, artificial intelligence and 
robotics; a technical, political and institutional map of emerging technologies, 2003, retrieved 
12. 04. 2010, <www.greenpeace.org.uk>. at 10. 
69 R Michalitsch, C Kallinger, Y Verbrandt, V Veefkind, & SR Huebner, ‘The Fullerene Patent 
Landscape in Europe’, Nanotechnology Law &Technology vol. 5, 2008, pp. 85. at 86. 
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relating to fullerenes, however only approximately 10% of those hold more than one; 
the US and Japan have had a higher patenting activity for fullerenes.70 
So far, fullerenes have found hardly any practical applications. Carbon nanotubes 
have done better in finding practical applications, these are however costly to produce 
and difficult to control,71 and it is predicted that these will be replaced by graphene as 
the material of choice in nano-enabled electronic devices.72 b) Graphene	  and	  Carbon	  Nanotubes	  
A carbon nanotube (CNT) is a rolled up sheet of graphene73 that can be produced in a 
variety of ways, however this is a very active area of research.74 In 2010, graphene 
which is being considered for the same types of applications as CNTs, was the subject 
of more than 3,000 research papers and more than 400 patent applications.75 Both 
materials are still quite challenging in their preparation, which in part explains the 
expansive patenting activity involving these two nanomaterials.76 
The first US patent application with the expression “carbon nanotube” appearing in 
the claims was filed in 1993.77 Since the year 2000 patent applications for inventions 
involving CNTs have undergone what is qualified as an explosive growth. The 
leading applicants are Samsung, Hon Hai, IBM, Intel, DuPont, Eastman Kodak, Fuji 
Xerox, NASA, Rice University, Nantero, Honda, Mitsubishi, Hyperion Catalysis 
International, and Applied Nanotech Holdings.78 The patenting of CNT has created 
what some authors call a patent thicket. Here the concern is that many of the 
applications or patents are wide in claim scope, and that their validity may questioned 
on other grounds. In particular the application of legal uncertainties in patent law 
doctrines such as patentable subject matter, novelty, obviousness, and enablement are 
thought to challenge CNT patent claims.79 
                                                
70 Ibid. 
71 R van Noorden, ‘Chemistry: The trials of new carbon.’, Nature vol. 469(7328), no. 7328, 
2011, pp. 14-16. 
72 AS Baluch, B Wilson, & JC Miller, ‘Patenting Graphene: Opportunities and Challenges’, 
Nanotechnology Law & Business vol. 5, 2008, pp. 289-299. 
73 Graphene is a single atom layer (atomically thin mesh) of carbon atoms arranged in a 
honeycomb (hexagonal) pattern. Because of the high strength of the carbon–carbon bonds in 
this allotrope of carbon, it has an exceptionally high strength-to-weight ratio; see 71. 
74 RM Frazier, DT Daly, RP Swatloski, KW Hathcock, & CR South, ‘Recent Progress in 
Graphene-Related Nanotechnologies’, Recent Patents on Nanotechnology vol. 3, no. 3, 2009, pp. 
164-176. 
75 See 71. 
76 See 74. 
77 U.S. Patent No. 5,346,683, filed Mar. 26, 1993, granted Sept. 13, 1994, inventors Green et al. 
78 MH Heines, ‘Carbon Nanotubes: Tracing the Growth of a Young Technology Through 
Patents’, Nanotechnology Law and Business vol. 7, 2010, pp. 21-37. 
79 See J Miller, & D Harris, ‘The Carbon Nanotube Patent Landscape’, Nanotechnology Law & 
Business vol. 3, 2006, pp. 427-454.; and for a detailed discussion of CNT patent thickets see D 
Harris, ‘Carbon Nanotube Patent Thickets’ in F Allhoff, & P Lin (eds.), Nanotechnology and 
Society: Current and Emerging Ethical Issues, Springer Netherlands, Dordrecht, 2009, pp. 163-
184. 
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The patenting of graphene has highlighted more of the already known problems with 
the patent system. Patent attorneys have argued the relevance of the obviousness 
doctrine post KSR International Co v Teleflex Inc80 where the Supreme Court rejected 
a rigid application of the so-called teaching, suggestion, or motivation81 test and 
invalidating a patent on the grounds of obviousness.82 Some argue that his ruling has 
in effect made it easier for US courts to rule an invention as obvious, thus not 
patentable, others interpret it as noticeably cautious and equivocal.83 The concern that 
arises in the particular case of graphene from the side of the patent attorney is that 
now CNT prior art can be held against graphene inventions and render them 
obvious.84 However for the purposes of this paper, obviousness considerations are not 
the focus of interest as these are to be taken into account once the presumed invention 
has been found to meet the criteria for being an invention as such, and ruled out as a 
discovery or a law of nature. We are concerned here with the issue of determining if 
the presumed invention is actually a discovery and how to effect that determination.  2. Self	  Assembling	  Peptides	  in	  Electronic	  Materials	  
As an example of how the patent information is being used to generate a narrative of 
concern, let us look at one specific example that is listed by the ETC Group in its 
latest report:85 the peptide claimed in US Patent 7,449,445where claim 1 reads: 
A conductive peptide nanofiber which comprises a nanofiber formed through a 
manner of self assembly of a peptide that has a nanofiber-forming ability and consist 
of a the amino acid sequence SEQ ID NO: 2 and a conductive substance added 
thereto, wherein, said conductive substance is being added to an amino group of said 
peptide.86  
This claim is for the amino acid sequence specified in the specification in the 
presence of a conductive substance, it does not claim self assembly as such, but 
makes use of molecular self assembly to create what is termed a nanofibre that can 
then be used for specific technological purposes. It is noteworthy that self assembly is 
better known among biological molecules than it is for those used for electronic 
devices.87 In fact, “it is one of the major chemist’s motivation to see that biology 
                                                
80 KSR International Co. v Teleflex Inc, 127 S. Ct 1727 (2007), decided April 30, 2007. 
81 The teaching, suggestion, or motivation (TSM) test serves to prevent against hindsight. “[A] 
patent claim is only proved obvious if ‘some motivation or suggestion to combine the prior art 
teachings’ can be found in the prior art, the nature of the problem, or the knowledge of a person 
having ordinary skill in the art.” in 80 at 1735. 
82 See 72. 
83 MJ Dowd, KC Bass III, & RG Sterne, ‘KSR International Co. v. Teleflex Inc.: Another Small 
Issue for Nanotechnology’, Nanotechnology Law & Business vol. 4, 2007, pp. 293-311. 
84 For a complete analysis of the issue of obviousness in the case of graphene in the US see: 
Baluch, Wilson, & Miller, Patenting Graphene: Opportunities and Challenges. 
85  Available at: http://www.etcgroup.org/documents/Com8788SpecialPNanoMar-
Jun05ENG.pdf (26.5.2011) 
86 US Patent 7,449,445, Conductive Peptide Nanofiber and Method of Manufacture of the Same, 
filed: Oct 19. 2005, granted Nov 11, 2008.  
87 H Choi, & CCM Mody, ‘The Long History of Molecular Electronics: Microelectronics 
Origins of Nanotechnology’, Social Studies Of Science vol. 39, no. 1, 2009, pp. 11-50; CA 
Hauser, ‘Nanotechnology: Peptides as biological semiconductors’, Nature vol. 468, 2010, pp. 
516-517.  
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successfully made highly complex properties on a molecular basis.”88 Furthermore 
synthetic biology – a further advance of science that shares with nanotechnology the 
close association of cognitive, technological and commercial aspects – is a project on 
the re-engineering of life and the utilization of life’s diverse solutions to process 
information, materials and energy.89 Molecular self assembly is, presumably 
unconsciously, often equated with living organisms. As a consequence this presumed 
mental equation often raises concerns among those with insufficiently detailed 
knowledge of the specifics of patent claim drafting. Thus the examination of such 
concerns as expressed in the vast literature of nanotechnology is of value in 
elucidating the relationship between the evolving frontier of science and the efforts of 
regulation. However before going into the technical details, one must not forget that 
all chemistry includes aspects of self-assembly some of which lead to 
macromolecules, others to crystal formation, and of course, there are also instances 
when elements or molecules will not chemically bond. That is, the use of self 
assembling molecules in an invention cannot possibly be construed as capturing a law 
of nature, or a discovery of such a natural law in the patent’s claim.  3. Mechanosynthesis	  of	  Diamond	  
Hailed as one of the first diamond mechanosynthesis patents, US Patent 7,687,146 
was granted on 30 March 2010; it has been classified as a nanotechnology invention. 
It claims a “capped tooltip molecule having a tip end and a nucleation-site handle end 
distal to the tip end, wherein the capped tooltip molecules comprises: one or more 
adamantane … ” The first independent claim goes on to specify a list of hundreds of 
chemical fragments all of which can be used with the capped carbon. It is hard to 
make a call on such a patent, and more difficult is the fact that given the breadth of 
choice of chemical entities in the claims, the wide scope pretentions of the 
specifications, and the scientific nature of the specification narrative, it may invite a 
challenge on several grounds (obviousness, scope, enablement). It could also be that 
this patent is an interesting exercise, but that it may never be the subject of either 
commercial-scale applicability, or a patent dispute and its existence would have 
served more of a public relations function than that of an intellectual or technical 
advance. The device in US Patent 7,687,146 is however one for molecular (diamond) 
fabrication, and in that respect is a Cartesian device; albeit complicated, it is not a 
complex system. 
B. The	  Size	  Arguments	  
When nanotechnology is mentioned, allusion is often made to size and the 
significance of size. We have so far refrained from these arguments because, from a 
chemical or scientific perspective, the size arguments are not relevant as these are 
representatives of a Cartesian model which does not apply at the quantum level. That 
is, from a chemical perspective, the size argument vanishes. However the size 
arguments must be heard for good reasons especially concerning occupational health 
issues affecting those working within the industry and for general regulatory purposes. 
In these non-patent related areas, size arguments are relevant because nano-sized 
                                                
88 B Bensaude-Vincent, ‘Two Cultures of Nanotechnology’ in J Schummer, & D Baird (eds.), 
Nanotechnology challenges: implications for philosophy, ethics and society, World Scientific 
Pub., 2006, pp. 7-28. at 17. 
89 Ibid. 
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particles can and will traverse the blood–brain barrier and their short and long term 
health effects must be considered in the regulatory effort.90 However the technical 
matter of patents raises other legal concerns and regulatory purposes, and size 
considerations have not yet provided for substantial case law. Nonetheless the EPO 
has heard and ruled on a case where size arguments were invoked. In BASF/Orica 
Australia91 the EPO rejected obviousness arguments based on synthesis temperature 
for polymer particles of 100 nm or less, where it argued that particle size was just a 
subordinate element. Size issues may be relevant in nanotechnology patents when 
they are included in the claims, as in Nanosized catalyst/General Electric below. In 
this case the deciding factor was the unity of the invention, not the size itself, even 
though the argument involved the method for size determination. In fact, the EC 
recommendation on the definition of nanomaterials alludes to the need to develop 
harmonized size measurement methods. 
C. Patent	  Disputes	  Involving	  Nanotechnology	  
The cases involving patent law and nanotechnology thus far can be qualified as the 
usual “legal skirmishes” and outside the scope of the invention–discovery 
dichotomy.92 At this time, there is no case law that can be used to cement the broad 
concerns about nano-patents invoked in the literature and cited in the introduction to 
this paper. So far the disputes involving nanotechnology patents do not stand out as 
stemming from nano-specific issues, but include those associated with patent thickets. 
For example, Nanosys, a 2001 US start-up that amassed a significant patent portfolio 
in a rather short time claimed infringement of their quantum dot patents by Nanoco 
Technologies (UK) and settled in 2009 when Nanoco agreed to terminate its current 
US business activities in quantum dots.93 Whether or not this case is an example of a 
patent thicket or of a set of “strong foundational patents of broad scope that have been 
shown to stifle innovation”94 is open to further analysis. Patent thickets in 
nanotechnology have received some attention.95 Several strategies have been 
considered to address this problem, among them patent pooling using standards or 
                                                
90 According to the EC recommendation referenced in 21, there is no unequivocal scientific 
basis to suggest a specific value for the size distribution of a nanomaterial as "a natural, 
incidental or manufactured material containing particles, in an unbound state or as an aggregate 
or as an agglomerate and where, for 50% or more of the particles in the number size distribution, 
one or more external dimensions is in the size range 1 nm – 100 nm." However the EC 
recommendation is subject to revision by December 2014. 
91 BASF/ Orica Australia Boards of Appeal of the EPO, T-0547/99 (8 January 2002). 
92 See also McLennan, & Rimmer, Cosmo, Cosmolino: patent law and nanotechnology.at 269-
70 
93 Nanosys Inc. v Nanoco Technologies Ltd., case number 09-cv-00259, in the U.S : District 
Court for the Western District of Wisconsin. See also Ibid. 
94 A Makker, ‘The Nanotechnology Patent Thicket and the Path to Commercialization’, 
Southern California Law Review vol. 84, 2011, pp. 1163-1403. 
95 R Bawa, ‘Will the nanomedicine “patent land grab” thwart commercialization?’, 
Nanomedicine: Nanotechnology, Biology and Medicine vol. 1, 2005, pp. 346-350; G Clarkson, 
& D DeKorte, ‘The problem of patent thickets in convergent technologies’, Annals of the New 
York Academy of Sciences vol. 1093, 2006, pp. 180-200; A Lee, ‘Examining the Viability of 
Patent Pools for the Growing Nanotechnology Patent Thicket’, Nanotechnology Law & 
Business vol. 3, no. 3, 2006, pp. 317-327; Miller, & Harris, The Carbon Nanotube Patent 
Landscape; J D’Silva, ‘Pools, Thickets and Open Source Nanotechnology’, European 
Intellectual Property Review vol. 31, no. 6, 2009, pp. 300-306.  
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reference models that provide a mechanism for clearing the nano-thickets and 
bringing nanotechnology-based products to the market.96 Another suggestion, in view 
of the growing number of nano patent thickets, and arguing on the basis of the 
information-physical-biological sciences convergence, is that of moving towards an 
open source model where the formation of patent pools is impractical.97 In an 
overview of questions of law and regulation concerning the patentability of inventions 
in the field of nanotechnology, the idea is advanced that “a certain risk of over-
patenting can theoretically be deduced.”98 However, patent thickets are a systemic 
problem, and not within the scope of the invention discovery distinction.  
Besides the already mentioned BASF/Orica Australia in 2002 heard at the EPO, what 
is arguably the first nanotech patent case in the US Federal Circuit – relating to an 
invention of alumina nanoparticles that are useful for chemical-mechanical polishing 
of ultra-smooth surfaces – was adjudicated on procedural grounds in 2005.99 Of 
significance in re Kumar is that the court treated the nanotechnology patent appeal no 
differently than patent appeals involving other technologies and that the court 
provides nanotech inventors with guidance for overcoming obviousness.100 However 
re Kumar while of interest in matters of obviousness, has nothing to offer that 
illuminates the concerns over the ownership of nature in terms of the invention–
discovery dichotomy, as this was not being challenged.  
Worth highlighting despite not addressing invention–discovery, is a patent 
infringement case of the nano-pharmaceutical reformulation of a breast cancer 
treatment. Although it does not deal with issues of patentability or patentable subject 
matter, it is of interest to give a flavour of the nature of the arguments used thus far 
when nanopatents are challenged. In Elan Pharma International Ltd v Abraxis 
BioScience Inc Ltd (06-438, US District Court, District of Delaware (Wilmington), 13 
June 2008) a jury delivered a US$ 55.2 million verdict to the plaintiff. The 
pharmaceutical concerned in this patent infringement dispute is paclitaxel  marketed 
as Taxol by the plaintiff Elan Pharmaceutical International (Elan) which filed the 
complaint in July 2006 alleging that the cancer treatment Abraxane, manufactured by 
Abraxis Biosciences (Abraxis) infringed two of Elan’s patents.101 Elan’s two patents 
claim a nanoparticle formulation aimed at enhancing the delivery of poorly water-
soluble paclitaxel (active ingredient) for the treatment of metastatic breast cancer.102 
Abraxane delivers the active ingredient in an efficient way while minimizing side 
effects using an albumin encapsulation. The patent claims in this case do involve a 
                                                
96 See Clarkson & DeKorte in 95. 
97 See D’Silva in 95.  
98 M Schellekens, ‘Patenting nanotechnology in Europe: Making a good start? An analysis of 
issues in law and regulation’, The Journal of World Intellectual Property vol. 13, no. 1, 2010, 
pp. 47-79.  
99 In re Kumar, 418 F. 3d 1361 - Court of Appeals, Federal Circuit 2005; vacated and remanded 
the decision of the Board of Patent Appeals and Interferences of the [U.S] Patent and Trademark 
Office. 
100 AS Baluch, L Radomsky, & SB Maebius, ‘In re Kumar: The First Nanotech Patent Case in 
the Federal Circuit’, Nanotechnology Law & Business vol. 2, no. 4, 2005, pp. 342-346. 
101 Elan Pharma. Int'l, Ltd. v. Abraxis Biosci., Inc., No. 06-438 (D. Del. filed July 19, 2006). 
102 WF Prendergast, & HN Schafer, ‘Nanocrystalline Pharmaceutical Patent Litigation: the First 
Case’, Nanotechnology Law & Business vol. 5, 2008, pp. 158-161. 
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nanomaterial and a pharmaceutical active ingredient; however the basis for the court’s 
decision was not on the nano-properties of the material. It rests on the fact that the 
alleged infringement involves the pharmaceutical active ingredient paclitaxel’s 
crystallinity (as opposed to an amorphous state). Thus while nanospecific elements 
were invoked, these were not decisive in the alleged infringement. 
In Nanosized catalyst/GENERAL ELECTRIC103 the EPO Technical Board of Appeal 
decided to dismiss the appeal of the examining division’s decision that the claims in 
application no.01985985.9 lacked unity. The board concluded that there is no reason 
to assume that there is a most common method of determining the average particle 
size in the direct synthesis of organohalosilanes, and that the methods available differ 
widely in the estimates produced. That is, while the claim specifies ‘average particle 
size of 0.1 to 600 nanometres’ the appellant refers to a method of preparation, but 
leaves the size determination unspecified, as referring only to “methods for 
determining the average particle size yielding values for the same particle distribution 
which generally differ, under particular conditions by one or two orders of 
magnitude.”104 This case was decided on the basis of  European Patent Convention 
(EPC) Article 84.105 There were no issues of patentability or discovery, rather the case 
points to problems in determining particle size. Depending on the method chosen, 
either based on volume, mass or area, the estimated particle size (expressed in 
nanometres) will vary by orders of magnitude. That the methodology would yield 
different estimates is neither surprising, nor arbitrary. The results are reproducible for 
each method. In addition, because nanotechnology is an emerging technology, it is 
also not surprising that there is no generally acceptable single method for particle size 
determination.  
IV. Chemistry Really: Nanomaterials and Molecules 
A. Ontological	  Views	  of	  Chemicals	  
Limiting the analysis to the reduction of nanomaterials, self-assembling peptides, 
genes, or biological active chemicals, to chemicals ignores more subtle ontological 
arguments which are significant in dealing with patenting issues. The so-called 
convergence in the nanotechnologies, synthetic biology, and smart materials 
engineering also necessitates a broadening of the discourse. That is, a Cartesian 
approach to chemical entities is too limiting as it ignores the complex nature of 
materials in general and nanotechnology-produced objects and aggregates in 
particular.106 We note that there is a difference if we consider a molecule in isolation 
or if we consider an aggregate of molecules.107 If we were to observe the carbon atom 
                                                
103 Board of Appeal of the EPO: T 1819/07 (15. 3. 2011). 
104 Ibid. at 3.2; An order of magnitude refers to a factor of ten, and two orders of magnitude to a 
factor of one hundred. 
105 European Patent Convention, 2007;The claims shall define the matter for which protection is 
sought. They shall be clear and concise and be supported by the description. 
106 See 47. 
107 The argument used by the majority opinion written by Judge Laurie in Myriad (29 July 2011) 
invokes the breaking of covalent chemical bonds, and is not an equivalent argument to the 
present one, albeit related. In fact, we suspect that this particular issue needs much more careful 
analysis than it has received thus far. 
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in isolation and study it in all its details subject to the available tools, we would still 
not know anything about diamonds or graphite that are aggregate states of that 
particular atom.108 In the case of carbon, the duplicity is multiplied because of the 
many kinds of chemical bonds that it forms.109 Thus, there is a difference if we 
consider a chemical entity (atom, molecule) in isolation, or if we consider it (or use it) 
in an aggregated state. An isolated atom and a crystal of the same atom belong to 
different functional categories. Nanoparticles of the same material fall between these 
two extreme phases of matter. So far, the patent regime has ignored the fundamental 
law of nature that is reflected in the uncontested observation that isolated and 
aggregated atoms or molecules exhibit naturally occurring properties which are very 
different.110 The consequence of ignoring this fact has led, for example, to equating a 
gene with a chemical compound and this paved the way to the gene’s patenting.111 
This shunting of the logic of materials in favour of what could be accommodated by 
existing (patent) regulations does pose technical and legal problems as evidenced in 
the cases discussed above. 
While strictly speaking both genes and ordinary chemicals are made of the same 
building blocks, that is, atoms, genes, unlike most conventional chemicals, operate at 
different functional levels. At the molecular level, and in isolation, genes or proteins 
can be categorized as chemicals. At the biological level genes code for one or more 
proteins, and at the whole organism level genes play roles related to the proteins they 
code for. That is, a gene in isolation is a sequence of molecules forming a chain of 
DNA. When part of a system, be it a cell, an organism, or a synthetic chemical 
medium, these same genes assume different functions as they interact with their 
immediate chemical or cellular environment (chemical environment, chemical 
context). As the scientific understanding of genes has progressed, the differentiation 
of the different levels of operation of these chemicals has emerged, and it allows for 
the questioning of the logic used to extend patentability to genes. As a result, we 
advance the notion that the “legal reduction of the gene to a chemical compound can 
no longer be supported in the context of the current practices of the scientific 
community.”112 Why is that? Because, as extensively discussed by Calvert and Joly, 
genes are very complex, there are diverse understandings of what the gene is, and in 
addition genes are essential facilities as in the sense of economics and antitrust law.113 
                                                
108 Analogous arguments can be constructed when the unit of aggregation is an atom instead of a 
molecule. 
109 The chemistry of carbon is a very extensive discipline on its own, usually designated as 
‘organic chemistry’ and that serves as a basis for the study of biological molecules or 
biochemistry. Biochemistry studies the functions of molecules as they are found in living 
organisms (plants and animals). Biotechnology involves the manipulation, transformation and 
exploitation of biological molecules for industrial processes. 
110 It is not just the patent regime that has ignored this universal fact. Chemical regulation is also 
plagued by the same fault whenever a material has several allotropic phases with dramatic 
differences in their properties. That is, carbon is not just carbon. Carbon is graphite, diamonds, 
carbon nanotubes, buckminsterfullerenes, to name but a few allotropes of carbon. 
111 J Calvert, & P-B Joly, ‘How did the gene become a chemical compound? The ontology of 
the gene and the patenting of DNA’, Social Science Information vol. 50, no. 2, 2011, pp. 157-
177. 
112 Ibid. at 168. 
113 Ibid. at 168 citing Henry, Tommmeter and Tubiana. Facilities are here to be understood as 
regulatory in a generic sense. This points to a limitation in the language in use. Genes have 
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What can be said for genes can also be extended to complex molecules and materials 
produced by the technologies enabled by mimetics and biomimetics. That is, the 
complexity which characterizes genes, proteins, or nanomaterials is the kind of 
complexity that a von Neumann complex machine possesses. The structures of genes, 
proteins, or nanomaterials can be described, but their function cannot be 
unambiguously described as in the case of a Cartesian machine such as a simple 
steam engine. At this point we are curious as to how chemical invention has been 
treated in patent law in the past, and pose the question of what the lessons from that 
history are. 
B. Highlights	  of	  the	  History	  of	  Chemical	  Invention	  
Throughout the history of the patent system the patentability of chemical inventions 
has been a subject of much debate and many changes in policy.114 Time and space 
contexts locate the patentability discipline as to the determination of what is eligible 
as patentable subject matter. This historical and regional contextual perspective helps 
in understanding the interplay between the economic, political, technological, 
industrial and scientific discourses, all of which feed into the patent regime. The 
question of what is fabricated and what is natural is not a new one; it preceded 
biotechnology by many years, if not centuries. Thus it is no surprise to find early 
arguments that a “novel true chemical compound” as such, is not entitled to patent 
protection. That is, chemical compounds, as such, cannot be inventions because a true 
invention is specifically a human affair.115 Thus the question is how chemical 
compounds ever came to be included as eligible patentable subject matter. The answer 
to this question is very different depending on the jurisdiction, and is often linked to 
the state of development of the national chemical industry.  
In part, we owe these developments of chemical invention in patent law to German 
chemists dexterity’s long history that brought the first synthetic dyes to the market. 
Largely without colonies from which to source raw materials, and wanting to reduce 
its trade deficit, Germany relied on coal tar as the raw material to effect substitutions 
through chemical transformations.116 The chemical industry was dominated by 
Germany as modern patent laws were being enacted in the late 1800s and early 1900s. 
British industry pressed for the abolition of patent protection for chemicals in the 
hope of being able to imitate German dyestuffs appearing on the British market so 
long as they could find an alternative process for their preparation. British patent 
lawmakers gave in and patent law was changed in 1919.117 
                                                                                                                                      
regulatory functions that are mediated (communicated) through chemicals acting on chemicals. 
Gene regulation is the result of short, medium and long range chemical interactions that may 
also be described alternatively with physical or physiological concepts and language.  
114 For an historical perspective of the international harmonization of the patent system see: 
Palombi, L. 2009. Gene cartels: biotech patents in the age of free trade. Edward Elgar. 
115 CE Ruby, ‘Patents for Acts of Nature’, Science, New Series vol. 89, no. 2313, 1939, pp. 387-
389; CE Ruby, ‘Patents for acts of nature’, Journal of Chemical Education vol. 16, no. 10, 1939, 
pp. 498. 
116 Leslie, E, Synthetic worlds, Reaktion Books, 2005. 
117 Grubb, PW, & PR Thomsen, Patents for Chemicals, Pharmaceuticals and Biotechnology: 
Fundamentals of Global Law, Practice and Strategy, Oxford University Press, USA, 2010. at 
16-26. 
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Germany had passed its first unitary patent law in 1877 ahead of the signing of the 
Paris Convention for the Protection of Industrial Property (Paris Convention) in 1883. 
This initial German patent law reflected the national chemical industry campaign 
against including patent protection for chemical substances.118 The rationale offered 
in 1877 for the exclusion of chemicals as such was that there are several processes 
using different starting materials that permit the synthesis of a chemical compound, 
and that to prevent these (through an absolute product claim for the chemical) would 
hinder the later invention of improved processes that would better serve the interests 
of the public and inventor.119 This logic got lost along the way, and now absolute 
chemical product protection (independent of process) is possible within some 
jurisdictions although this has been late in coming even in industrialized nations such 
as Germany, Japan, the Netherlands, and Switzerland (1968-1978).120 The early 
distinction between product and process and their respective eligibility as patentable 
subject matter in the context of chemical invention must be noted and emphasized as 
it suggests viable options for getting out of the quandary when seeking patent 
protection for convergence chemical inventions that are the products of a combination 
of biotechnology, nanotechnology, and bio nanotechnology. 
Switzerland did not have a patent law until 1888, that is, five years after the Paris 
Convention was signed, and was a ‘patent piracy’ country where the products of the 
German chemical industry were imitated. The historical record shows that the founder 
of Geigy AG (later incorporated into Ciba-Geigy, then Novartis) denounced patents 
as a paradise for parasites.121 Until 1888 Swiss products could be imported and sold in 
Germany because up to that time German industry had refused to accept product 
protection in its patent law  while chemical processes were patentable. It was only in 
1888 after the German BASF successfully sued the Swiss Geigy for infringement for 
selling in Germany a dye produced in Switzerland by a BASF-patent-protected 
process that the codification of the indirect product protection was included in 
                                                
118 The German Patentgesetz of 25 May 1877 defines patentable subject matter and exclusions 
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119 See: Zimmerman, PA, Patentwesen in der Chemie: Ursprunge Anfänge Entwicklung, 
Badische Anilin- & Sodafabrik AG, Ludwigshafen am Rhein, 1965. at 36. 
120 See 117 at 77.  
121 Ibid. at 25. 
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German patent law in 1891. This reflects the fact that initially (1877) the sale of the 
product of a patented process was thought not to constitute infringement. However the 
Swiss patent law as enacted in 1888 excluded both substances and processes from 
protection as it required a ‘working model’ that demonstrated the invention. Product 
protection came in much later, in 1978. However, processes had already been 
protected since the 1907 enactment. The US Patent Act of 1790 established a very 
strict examination procedure, and it granted its first patent for a chemical invention – 
not a chemical compound – relating to the manufacture of pearl ash (potassium 
carbonate).122 
C. Divergence	  of	  Technology	  and	  Patent	  Law	  
Science and technology advancements and revisions to patent law have moved along 
different trajectories. At least from a science and technology point of view the 
developments have not been congruent. That is, while science and technology have 
moved ahead by leaps and bounds, patent law has neither conserved its original 
design, nor has it kept pace with the developments in the basic arts feeding into the 
industries and publics that it serves. The subsequent patent law revisions have ignored 
any serious attempts at bringing its substance in line with the emerging technologies 
of the twentieth and twenty-first centuries such as digital technology, biotechnology, 
nanotechnology or synthetic biology. Instead, incongruent divergence between patent 
law and the technologies that it aims to encourage and harbour has proceeded 
uncorrected. These days patent law in most jurisdictions attends to a myriad of anti-
competitive and special interests and ignores most of the more up to date and 
fundamental aspects of intellectual property. The recital in Article 7 TRIPS is clear 
that “[t]he protection and enforcement of intellectual property rights should contribute 
to the promotion of technological innovation and to the transfer and dissemination of 
technology, to the mutual advantage of producers and users of technological 
knowledge and in a manner conducive to social and economic welfare, and to a 
balance of rights and obligations.”123 
What is also clear is that at its inception, the patent system was not intended to deal 
with chemical invention (complex engines); rather it was designed to deal with 
mechanical inventions at a macroscopic scale, the so-called Cartesian machines 
(simple engines). When you place several pieces of wood together, they do not, 
according to the laws of nature assemble themselves into a chair, however, when the 
components necessary to synthesize acetyl salicylic acid are placed together, they can 
not help but react to form the chemical compound. Thus these components do 
assemble spontaneously (self-assembly) and under the direct influence of the laws of 
nature. Human ingenuity plays a role in chemical invention when it comes to applying 
knowledge about the conditions most favourable for the chemical reaction.  
Quantum mechanics had not yet even been conceived and the chemical industry was 
at best embryonic and just emerging from the shadows of alchemy and sorcery when 
the first patent laws were being enacted. In allowing chemical processes as patentable 
subject matter, the patent system adjusted to the fruits of the industrial revolution 
without consideration as to the differences between Cartesian machines and von 
Neumann complex machines.  
                                                
122 Ibid. at 20.  
123 TRIPS Article 7. 
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Obfuscating all earlier reason are the interpretation and arguments that patent 
practitioners in the pharmaceutical industries have presented to have things their way. 
The most frequently invoked argument for the patent protection of active 
pharmaceutical ingredients (chemicals) are those of investment protection and 
providing incentives for innovation. However, neither of these arguments can be 
brought to bear through empirical studies.124 There is the inevitable argument that in 
the pharmaceuticals industry, patent protection prevents the proliferation of 
formulations and active ingredients as trade secrets which supposedly would hamper 
innovation and deprive the public domain of that specific information. While we 
agree that secrecy in pharmaceuticals is not a desirable option, we remain 
unconvinced that the patent system is the appropriate regulatory instrument for 
guaranteeing disclosure of pharmaceutical formulations and active ingredients. 
Pharmaceuticals are subject to additional regulatory procedures, such as market 
approval after presentation of the required clinical trial results, that could well also 
require complete formulation and active ingredients disclosure.  
With nanotechnology, the concept of invention and the patent regime may fail further 
when considering inventions resulting from biomimetics and mimetics. These 
inventions will be complex machines à von Neumann, just like chemicals. It is this 
type of invention that the present substantive patent law is not equipped to deal with. 
Evidence of this lacuna is provided by the remedy supplied by the special treatment of 
chemical and biotechnology inventions. This inherent failure of substantive patent law 
to deal with complex machines could be invoked to explain the chemical industry’s 
vacillation as to the suitability of the patent system for their purposes. After all, 
chemicals, all chemicals, including macromolecules which are beautifully illustrated 
by their enablement as genes, are complex machines. 
Science and technology have diverged from the patent system because while the 
patent system was designed to deal with Cartesian machines or simple engines, 
science and technology have advanced and are now capable of inventing complex 
engines. Thus today’s engineering teams are manufacturing devices which are 
increasingly complex and which cannot be compared with the objects manufactured 
in the late nineteenth and twentieth centuries. As a technological society, we have 
moved past steam engines and mechanical watches to digital technologies driven by 
complex machines components, such as those found in smart phones.  
The bigger question that we see emerging from the considerations above is whether 
the principles of patent law concocted at the beginning of the industrial revolution at 
the end of the nineteenth century to accommodate the industrial fabrication of simple 
machines and mechanical devices are adequate and sufficient to cope with the 
engineering of molecular processes. We suspect that they are not and take 
nanotechnology as a case study to ask some fundamental questions about the 
foundational building blocks of patent law in a globalized, digital and ever more 
complex world. 
                                                
124 For a discussion of the patent system in terms of its functionality as a legal device of wide 
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V. Diagnosis 
In the this paper we looked into the broad concerns about nanotechnology patents 
including an examination of a patent including self-assembling peptides in electronic 
materials125 that had been identified as exemplary for the concern, but soon found 
these not to be specific to nanotechnology. The initial concern voiced by Bowman126 
that a broad interpretation of Article 27 TRIPS may result in the monopolization of 
fundamental molecules and compounds via the patent system merits discussion 
because nanomaterials are, as we argue from an ontological perspective, for all 
practical purposes of science and law, chemicals.127 Hence what is at issue is the 
patenting of chemicals, not the patenting of inventions issuing from technologies 
using methodologies and applying scientific principles associated with the conceptual 
narrative of nanotechnology.128 In our analysis we find no evidence that either “the 
very broad interpretation or loose definitions used to describe nanotechnology”129 act 
to weaken the protection afforded by the patent system for two reasons. First, there is 
no recognized single and distinct technology as such that is designated by the term 
nanotechnology. Instead we find that an ensemble of methods and principles under 
the umbrella of nanotechnology can be applied in any technological area, as can be 
seen by the distribution of nano-patents across a broad range of patent classifications. 
Second, the legal battles fought so far over nanotechnology patents have not taken 
issue with either invention as such, the scope of the claims, or with any issue in 
substantive patent law. However the concern remains that there are patents that 
protect the mere discovery of such objects as “human cells, umbilical cells, plant 
genes.”130 We reiterate that all of these concerns revolve around what constitutes 
chemical invention. Hence there are two fundamental issues at stake. One is what 
constitutes invention, and the second is what constitutes chemical invention as a 
special case of invention. In this paper we have identified that what constitutes 
chemical invention is worthy of a new appraisal in light of nanotechnology methods 
and the research and development drive towards the imitation of nature to invent new 
materials. 
The concerns about nanotechnology patents are old concerns about the logic and 
practice of the patent law and are symptomatic of much that is dysfunctional in patent 
law. From our perspective there are two categories of problems that need to be 
addressed if one is to bring back the full functionalities of stimulating innovation, 
technological development and the diffusion or dissemination of technical 
information and knowledge. On one side we have problems with substantive patent 
law as to the scope of patentable subject matter, and on the other side, there are 
systemic problems involving patent thickets, patent pools, freedom to operate and 
transparency, and the complexity of emerging technologies. In this paper we 
                                                
125 See section Self Assembling Peptides in Electronic Materials. 
126 See 5. 
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128 For a detailed discussion of the narrative dimension of nanotechnology see E Mordini, ‘The 
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introduce the distinction between simple and complex machines as these relate to 
chemistry and nanotechnology, the point being that chemicals are complex machines 
whose behaviour is more extensive than our representational methods can describe. 
This distinction poses the question of what is the logical category of inventions that 
fall within patentable subject matter given that patent law was conceived to cover 
simple machines, not complex ones. This question emerges naturally because most of 
the problems documented elsewhere in the case law revolve around the patenting of 
genes which are chemicals and naturally occurring.131 We find that the concern over 
nanotechnology patents should be focused elsewhere. This concern should be directed 
towards determining the desirability or not of maintaining chemicals as such as 
eligible patent subject matter.  
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